Carlo Gabriele Tocchetti

List of Publications by Year
in descending order

187 papers	17,127 citations	25034 57 h-index	17592 121 g-index
204 all docs	204 docs citations	204 times ranked	15826 citing authors

#	Article	IF	Citations
1	Direct oral anticoagulants across the heart failure spectrum: the precision medicine era. Heart Failure Reviews, 2022, 27, 135-145.	3.9	2
2	Novel actors on the stage of cardiac dysfunction induced by anti-PD1 oncological treatments. European Heart Journal, 2022, 43, 330-332.	2.2	6
3	Pathophysiology of Takotsubo syndromeÂâ€" a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of CardiologyÂâ€"ÂPart 2: vascular pathophysiology, gender and sex hormones, genetics, chronic cardiovascular problems and clinical implications. European Journal of Heart Failure, 2022, 24, 274-286.	7.1	34
4	Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: The HFA/ICOS risk tool in real-world practice. International Journal of Cardiology, 2022, 349, 134-137.	1.7	11
5	Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study. International Journal of Cardiology, 2022, 350, 62-68.	1.7	13
6	Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2022, 24, 406-420.	7.1	22
7	Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2022, 118, 3016-3051.	3.8	30
8	Education and certification on heart failure of the <scp>H</scp>eart <scp>F</scp>ailure <scp>A</scp>ssociation of the <scp>E</scp>uropean <scp>S</scp>ociety of <scp>C</scp>ardiology. European Journal of Heart Failure, 2022, 24, 249-253.	7.1	6
9	Cardiovascular events and treatment of children with high risk medulloblastoma. EClinicalMedicine, 2022, 43, 101251.	7.1	1
10	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	7.1	820
11	Mitochondrial Creatine Kinase Attenuates Pathologic Remodeling in Heart Failure. Circulation Research, 2022, , CIRCRESAHA121319648.	4.5	6
12	Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan. ESC Heart Failure, 2022, 9, 1107-1117.	3.1	12
13	HNO Protects the Myocardium against Reperfusion Injury, Inhibiting the mPTP Opening via PKCÎµ Activation. Antioxidants, 2022, 11, 382.	5.1	6
14	Cardiac remodellingÂâ€"ÂPart 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 927-943.	7.1	29
15	Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. Frontiers in Immunology, 2022, 13, 804597.	4.8	27
16	A PI3KÎ³ mimetic peptide triggers CFTR gating, bronchodilation, and reduced inflammation in obstructive airway diseases. Science Translational Medicine, 2022, 14, eabl6328.	12.4	6
17	Impact of a cardioâ€oncology unit on prevention of cardiovascular events in cancer patients. ESC Heart Failure, 2022, 9, 1666-1676.	3.1	9
18	Janus, or the Inevitable Battle Between Too Much and Too Little Oxygen. Antioxidants and Redox Signaling, 2022, 37, 972-989.	5.4	7

#	Article	IF	Citations
19	CardiacremodellingÂâ€“ÂPart 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 944-958.	7.1	22
20	Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF. ESC Heart Failure, 2022, 9, 2909-2917.	3.1	10
21	Towards standardization of echocardiography for the evaluation of left ventricular function in adult rodents: a position paper of the ESC Working Group on Myocardial Function. Cardiovascular Research, 2021, 117, 43-59.	3.8	72
22	Cancer Risk in the Heart Failure Population: Epidemiology, Mechanisms, and Clinical Implications. Current Oncology Reports, 2021, 23, 7.	4.0	12
23	Timeâ€weighted lactate as a predictor of adverse outcome in acute heart failure. ESC Heart Failure, 2021, 8, 539-545.	3.1	10
24	Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC). European Heart Journal Cardiovascular Imaging, 2021, 22, 406-415.	1.2	16
25	Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors. Current Oncology Reports, 2021, 23, 13.	4.0	38
26	Metabolic Aspects of Anthracycline Cardiotoxicity. Current Treatment Options in Oncology, 2021, 22, 18.	3.0	48
27	Low-intensity pulsed ultrasound (LIPUS) in heart failure with preserved ejection fraction (HFpEF):lupus in fabula?. Cardiovascular Research, 2021, 117, 1238-1240.	3.8	1
28	Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. , 2021, 9, e002007.		36
29	Cardiovascular safety of the tyrosine kinase inhibitor nintedanib. British Journal of Clinical Pharmacology, 2021, 87, 3690-3698.	2.4	8
30	How can we manage the cardiac toxicity of immune checkpoint inhibitors?. Expert Opinion on Drug Safety, 2021, 20, 1-10.	2.4	8
31	Noncardiovascular comorbidities in patients with heart failure and their impact on prognosis. Kardiologia Polska, 2021, 79, 493-502.	0.6	3
32	The multifaceted mechanisms of nitroxyl in heart failure: inodilator or â€˜onlyâ€™ vasodilator?. European Journal of Heart Failure, 2021, 23, 1156-1159.	7.1	4
33	New-Onset Cancer in the HF Population: Epidemiology, Pathophysiology, and Clinical Management. Current Heart Failure Reports, 2021, 18, 191-199.	3.3	5
34	Understanding the heart-brain axis response in COVID-19 patients: A suggestive perspective for therapeutic development. Pharmacological Research, 2021, 168, 105581.	7.1	26
35	Oxidative stress in anticancer therapies-related cardiac dysfunction. Free Radical Biology and Medicine, 2021, 169, 410-415.	2.9	5
36	Current gaps in HFpEF trials: Time to reconsider patients' selection and to target phenotypes. Progress in Cardiovascular Diseases, 2021, 67, 89-97.	3.1	12

#	Article	IF	Citations
37	Targeting fibrosis in the failing heart with nanoparticles. Advanced Drug Delivery Reviews, 2021, 174, 461-481.	13.7	20
38	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	2.2	5,558
39	Reciprocal organ interactions during heart failure: a position paper from the ESC Working Group on Myocardial Function. Cardiovascular Research, 2021, 117, 2416-2433.	3.8	27
40	<scp>COVID</scp>â€19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 1806-1818.	7.1	32
41	Prevention of cancer therapy-related heart failure, is it really possible?. Journal of Cardiovascular Medicine, 2021, 22, 441-443.	1.5	1
42	Prognostic impact of diabetes in chronic and acute heart failure. Heart Failure Reviews, 2021, , 1.	3.9	1
43	Metabolic remodelling of glucose, fatty acid and redox pathways in the heart of type 2 diabetic mice. Journal of Physiology, 2020, 598, 1393-1415.	2.9	34
44	Autophagy and cancer therapy cardiotoxicity: From molecular mechanisms to therapeutic opportunities. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118493.	4.1	27
45	Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure. European Journal of Internal Medicine, 2020, 71, 23-31.	2.2	29
46	Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the <scp>Cardioâ€Oncology Study Group</scp> of the <scp>Heart Failure Association</scp> and the <scp>Cardioâ€Oncology Council of the European Society of Cardiology</scp>. European Journal of Heart Failure, 2020, 22, 1966-1983.	7.1	184
47	Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. Cardiovascular Research, 2020, 116, 1820-1834.	3.8	51
48	Redox Imbalances in Ageing and Metabolic Alterations: Implications in Cancer and Cardiac Diseases. An Overview from the Working Group of Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology (SIC). Antioxidants, 2020, 9, 641.	5.1	23
49	Sexâ€related differences in COVIDâ€19 lethality. British Journal of Pharmacology, 2020, 177, 4375-4385.	5.4	69
50	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the <scp>Translational Research Committee</scp> of the <scp>Heart Failure Association</scp> (<scp>HFA</scp>) of the <scp>European Society of Cardiology</scp> (<scp>ESC</scp>). European Journal of Heart Failure, 2020, 22, 2272-2289.	7.1	92
51	Commentary on â€œFunctional Improvement After Outpatient Cardiac Rehabilitation in Acute Coronary Syndrome Patients is not Related to Improvement in Left Ventricular Ejection Fractionâ€. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 179-181.	2.2	0
52	Cardiomyocyte ageing and cardioprotection: consensus document from the ESC working groups cell biology of the heart and myocardial function. Cardiovascular Research, 2020, 116, 1835-1849.	3.8	34
53	Stimulating pro-reparative immune responses to prevent adverse cardiac remodelling: consensus document from the joint 2019 meeting of the ESC Working Groups of cellular biology of the heart and myocardial function. Cardiovascular Research, 2020, 116, 1850-1862.	3.8	22
54	Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the <scp>C</scp>ardioâ€<scp>O</scp>ncology <scp>S</scp>tudy <scp>G</scp>roup of the <scp>H</scp>eart <scp>F</scp>ailure <scp>A</scp>ssociation of the <scp>E</scp>uropean <scp>S</scp>ociety of <scp>C</scp>ardiology in collaboration with the <scp>I</scp>nternational <scp>C</scp>ardioâ€<scp>O</scp>ncology <scp>S</scp>ociety. European Journal of Heart Failure, 2020,	7.1	364

#	Article	IF	Citations
55	Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitorâ€“Associated Myocarditis. Circulation, 2020, 141, 2031-2034.	1.6	142
56	Non-coding RNAs: update on mechanisms and therapeutic targets from the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. Cardiovascular Research, 2020, 116, 1805-1819.	3.8	39
57	Pulmonary Hypertension Phenotypes in Systemic Sclerosis: The Right Diagnosis for the Right Treatment. International Journal of Molecular Sciences, 2020, 21, 4430.	4.1	20
58	Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the <scp>H</scp>eart <scp>F</scp>ailure <scp>A</scp>ssociation (<scp>HFA</scp>), the <scp>E</scp>uropean <scp>A</scp>ssociation of <scp>C</scp>ardiovascular <scp>I</scp>maging (<scp>EACVI</scp>) and the <scp>Cardioâ€Oncology C</scp>ouncil of the <scp>E</scp>uropean <scp>S</scp>ociety of <scp>C</scp>ardiology (<scp>ESC</scp>). European Journal of Heart Failure, 2020, 22, 1504-1524.	7.1	234
59	Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib. Heart Failure Reviews, 2020, 25, 447-456.	3.9	15
60	Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. European Heart Journal, 2020, 41, 1733-1743.	2.2	212
61	Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. Journal of the American College of Cardiology, 2020, 75, 467-478.	2.8	179
62	Bmi1 inhibitor PTC-209 promotes Chemically-induced Direct Cardiac Reprogramming of cardiac fibroblasts into cardiomyocytes. Scientific Reports, 2020, 10, 7129.	3.3	28
63	Physical vs. multidimensional frailty in older adults with and without heart failure. ESC Heart Failure, 2020, 7, 1371-1380.	3.1	16
64	Adapted recreational football small-sided games improve cardiac capacity, body composition and muscular fitness in patients with type 2 diabetes. Journal of Sports Medicine and Physical Fitness, 2020, 60, 1261-1268.	0.7	2
65	Cardiac sympathetic dysfunction in pulmonary arterial hypertension: lesson from leftâ€sided heart failure. Pulmonary Circulation, 2019, 9, 1-10.	1.7	13
66	Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens. Heart Failure Reviews, 2019, 24, 915-925.	3.9	39
67	Novel Therapeutic Strategies for the Treatment of Chronic Diseases. Current Medicinal Chemistry, 2019, 26, 2788-2790.	2.4	1
68	What Is the Cardiac Impact of Chemotherapy and Subsequent Radiotherapy in Lymphoma Patients?. Antioxidants and Redox Signaling, 2019, 31, 1166-1174.	5.4	21
69	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 272-285.	7.1	182
70	Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovascular Research, 2019, 115, 854-868.	3.8	311
71	Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients. Cardiac Failure Review, 2019, 5, 112-118.	3.0	39
72	Modulation of Redox Signaling in Chronic Diseases and Regenerative Medicine. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-4.	4.0	0

#	Article	IF	Citations
73	Inflammatory, Serological and Vascular Determinants of Cardiovascular Disease in Systemic Lupus Erythematosus Patients. International Journal of Molecular Sciences, 2019, 20, 2154.	4.1	26
74	Mitochondrial Creatine Kinase Attenuates ROS Emission and Improves Myocyte Survival after ROS in the Failing Heart. Biophysical Journal, 2019, 116, 156a.	0.5	0
75	The novel butyrate derivative phenylalanineâ€butyramide protects from doxorubicinâ€induced cardiotoxicity. European Journal of Heart Failure, 2019, 21, 519-528.	7.1	80
76	Nitroxyl (HNO) targets phospholamban cysteines 41 and 46 to enhance cardiac function. Journal of General Physiology, 2019, 151, 758-770.	1.9	26
77	The continuous heart failure spectrum: moving beyond an ejection fraction classification. European Heart Journal, 2019, 40, 2155-2163.	2.2	195
78	Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. , 2019, 7, 53.		59
79	Recent advances in cardioâ€oncology: a report from the â€˜Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019â€™. ESC Heart Failure, 2019, 6, 1140-1148.	3.1	34
80	Permanent atrial fibrillation and pulmonary embolism in elderly patients without deep vein thrombosis: is there a relationship?. Aging Clinical and Experimental Research, 2019, 31, 1121-1128.	2.9	8
81	Treatments targeting inotropy. European Heart Journal, 2019, 40, 3626-3644.	2.2	123
82	Pulmonary Hypertension Induced by Anticancer Drugs. Current Clinical Pathology, 2019, , 133-139.	0.0	1
83	From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview. Antioxidants and Redox Signaling, 2019, 30, 2110-2153.	5.4	96
84	Mechanisms of Cardiovascular Damage Induced by Traditional Chemotherapy. Current Clinical Pathology, 2019, , 3-14.	0.0	0
85	Molecular Mechanisms of Cardiovascular Damage Induced by Anti-HER-2 Therapies. Current Clinical Pathology, 2019, , 15-19.	0.0	0
86	Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. European Journal of Heart Failure, 2018, 20, 879-887.	7.1	138
87	Pulmonary arterial hypertension and atrial arrhythmias: incidence, risk factors, and clinical impact. Pulmonary Circulation, 2018, 8, 1-8.	1.7	43
88	The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC. European Journal of Heart Failure, 2018, 20, 445-459.	7.1	118
89	Phosphoinositide 3-Kinase Gamma Inhibition Protects From Anthracycline Cardiotoxicity and Reduces Tumor Growth. Circulation, 2018, 138, 696-711.	1.6	145
90	Cardiac Toxicity in Patients Treated With Immune Checkpoint Inhibitors. Journal of the American College of Cardiology, 2018, 71, 1765-1767.	2.8	49

#	Article	IF	Citations
91	Severe Aortic Valve Regurgitation in Relapsing Polychondritis. Journal of Clinical Rheumatology, 2018, 24, 109-111.	0.9	1
92	An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 216-227.	7.1	81
93	Pharmacovigilating cardiotoxicity of immune checkpoint inhibitors. Lancet Oncology, The, 2018, 19, 1545-1546.	10.7	16
94	Novel Therapeutic Approaches and Targets for the Treatment of Cardiovascular and Immunological Diseases. Current Pharmaceutical Biotechnology, 2018, 19, 684-685.	1.6	0
95	Modernâ€day cardioâ€oncology: a report from the â€˜Heart Failure and World Congress on Acute Heart Failure 2018â€™. ESC Heart Failure, 2018, 5, 1083-1091.	3.1	23
96	Right heart dysfunction. Journal of Cardiovascular Medicine, 2018, 19, 613-623.	1.5	10
97	Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. Cardiovascular Research, 2018, 114, 1287-1303.	3.8	91
98	Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production. Frontiers in Physiology, 2018, 9, 38.	2.8	36
99	Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective. Frontiers in Physiology, 2018, 9, 167.	2.8	118
100	Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. Cardiovascular Research, 2018, 114, 1273-1280.	3.8	64
101	Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue. Current Medicinal Chemistry, 2018, 25, 1327-1339.	2.4	99
102	Allele-specific differences in transcriptome, miRNome, and mitochondrial function in two hypertrophic cardiomyopathy mouse models. JCI Insight, 2018, 3, .	5.0	33
103	Intracardiac metastasis originated from chondrosarcoma. Journal of Cardiovascular Medicine, 2017, 18, 385-388.	1.5	4
104	The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2017, 19, 1361-1378.	7.1	115
105	Cardiac Toxicity of Immune Checkpoint Inhibitors. Circulation, 2017, 136, 1989-1992.	1.6	83
106	Cardiotoxicity of immune checkpoint inhibitors. ESMO Open, 2017, 2, e000247.	4.5	186
107	Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond. International Journal of Cardiology, 2017, 227, 11-17.	1.7	64
108	Nanotechnology-Based Cardiac Targeting and Direct Cardiac Reprogramming: The Betrothed. Stem Cells International, 2017, 2017, 1-12.	2.5	22

#	Article	IF	Citations
109	The Influence of Fiber on Gut Microbiota: Butyrate as Molecular Player Involved in theÂBeneficial Interplay BetweenÂDietary Fiber and Cardiovascular Health. , 2017, , 61-71.		4
110	Novel Perspectives in Redox Biology and Pathophysiology of Failing Myocytes: Modulation of the Intramyocardial Redox Milieu for Therapeutic Interventionsâ€"A Review Article from the Working Group of Cardiac Cell Biology, Italian Society of Cardiology. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-13.	4.0	10
111	Pathophysiology of anthracycline cardiotoxicity. Journal of Cardiovascular Medicine, 2016, 17, e3-e11.	1.5	31
112	Role of biomarkers in monitoring antiblastic cardiotoxicity. Journal of Cardiovascular Medicine, 2016, 17, e27-e34.	1.5	18
113	A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity. Journal of Cardiovascular Medicine, 2016, 17, e84-e92.	1.5	47
114	A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity. Journal of Cardiovascular Medicine, 2016, 17, e93-e104.	1.5	37
115	Cardiovascular imaging in the diagnosis and monitoring of cardiotoxicity. Journal of Cardiovascular Medicine, 2016, 17, e35-e44.	1.5	20
116	Cardiac Over-Expression of Creatine Kinase Differentially Affects Cardiomyocyte Function in Ischemic and Non-Ischemic Heart Failure. Biophysical Journal, 2016, 110, 599a.	0.5	0
117	Models of Heart Failure Based on the Cardiotoxicity of Anticancer Drugs. Journal of Cardiac Failure, 2016, 22, 449-458.	1.7	60
118	Biomarkers in sarcopenia: A multifactorial approach. Experimental Gerontology, 2016, 85, 1-8.	2.8	145
119	Preventing antiblastic drug-related cardiomyopathy. Journal of Cardiovascular Medicine, 2016, 17, e64-e75.	1.5	23
120	Current views on anthracycline cardiotoxicity. Heart Failure Reviews, 2016, 21, 621-634.	3.9	39
121	Testosterone Antagonizes Doxorubicinâ€Induced Senescence of Cardiomyocytes. Journal of the American Heart Association, 2016, 5, .	3.7	62
122	Bidirectional cross-regulation between ErbB2 and Î²-adrenergic signalling pathways. Cardiovascular Research, 2016, 109, 358-373.	3.8	44
123	Cardiac Over-Expression of Creatine Kinase Improves Function in Failing Myocytes. Biophysical Journal, 2015, 108, 595a.	0.5	1
124	Impaired mitochondrial energy supply coupled to increased H2O2 emission under energy/redox stress leads to myocardial dysfunction during TypeÂI diabetes. Clinical Science, 2015, 129, 561-574.	4.3	37
125	Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs. BioMed Research International, 2015, 2015, 1-14.	1.9	34
126	Restoring redox balance enhances contractility in heart trabeculae from type 2 diabetic rats exposed to high glucose. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 308, H291-H302.	3.2	42

#	Article	IF	Citations
127	Protective Mechanisms of Mitochondria and Heart Function in Diabetes. Antioxidants and Redox Signaling, 2015, 22, 1563-1586.	5.4	59
128	Constitutive BDNF/TrkB signaling is required for normal cardiac contraction and relaxation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1880-1885.	7.1	96
129	Cardioprotection by gene therapy. International Journal of Cardiology, 2015, 191, 203-210.	1.7	34
130	Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection. Heart Failure Reviews, 2015, 20, 621-631.	3.9	40
131	Nitroso-Redox Balance and Modulation of Basal Myocardial Function: An Update from the Italian Society of Cardiovascular Research (SIRC). Current Drug Targets, 2015, 16, 895-903.	2.1	25
132	Endogenous Cardioprotective Agents: Role in Pre and Postconditioning. Current Drug Targets, 2015, 16, 843-867.	2.1	47
133	Mitral peak early diastolic filling velocity to deceleration time ratio as a predictor of prognosis in patients with chronic heart failure and preserved or reduced ejection fraction. Journal of Geriatric Cardiology, 2015, 12, 346-52.	0.2	4
134	<scp>ESC</scp> Working Group on Myocardial Function Position Paper: how to study the right ventricle in experimental models. European Journal of Heart Failure, 2014, 16, 509-518.	7.1	11
135	Targeting myocardial remodelling to develop novel therapies for heart failure. European Journal of Heart Failure, 2014, 16, 494-508.	7.1	90
136	CCR5 Inhibition Prevents Cardiac Dysfunction in the SIV/Macaque Model of HIV. Journal of the American Heart Association, 2014, 3, e000874.	3.7	25
137	Ranolazine protects from doxorubicinâ€induced oxidative stress and cardiac dysfunction. European Journal of Heart Failure, 2014, 16, 358-366.	7.1	76
138	Nitroxyl (HNO) for Treatment of Acute Heart Failure. Current Heart Failure Reports, 2014, 11, 227-235.	3.3	36
139	HNO Enhances SERCA2a Activity and Cardiomyocyte Function by Promoting Redox-Dependent Phospholamban Oligomerization. Antioxidants and Redox Signaling, 2013, 19, 1185-1197.	5.4	74
140	Aldose Reductase Inhibition or Activation of Transketolase Offset Adverse Metabolic Remodeling Improving Function in Type 2 Diabetes Myocytes Exposed to Hyperglycemia. Biophysical Journal, 2013, 104, 159a.	0.5	1
141	Nitroxyl (HNO). Circulation: Heart Failure, 2013, 6, 1250-1258.	3.9	109
142	Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: two cases and review of the literature. Future Oncology, 2013, 9, 127-133.	2.4	2
143	Glutathione oxidation unmasks proarrhythmic vulnerability of chronically hyperglycemic guinea pigs. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 304, H916-H926.	3.2	20
144	The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors. European Journal of Heart Failure, 2013, 15, 482-489.	7.1	61

#	Article	IF	Citations
145	Utility of 2D-speckle tracking echocardiography in diagnosis of left ventricular dysfunction in anti-ErbB2 therapy.. Journal of Clinical Oncology, 2013, 31, 169-169.	1.6	0
146	Inhibition of cardiomyocytes late INa with ranolazine to prevent anthracyclines cardiotoxicity in experimental models in vitro and in vivo.. Journal of Clinical Oncology, 2013, 31, 170-170.	1.6	0
147	Oxidative and nitrosative stress in the maintenance of myocardial function. Free Radical Biology and Medicine, 2012, 53, 1531-1540.	2.9	85
148	Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. Journal of Molecular and Cellular Cardiology, 2012, 52, 1213-1225.	1.9	1,053
149	GSH or Palmitate Preserves Mitochondrial Energetic/Redox Balance, Preventing Mechanical Dysfunction in Metabolically Challenged Myocytes/Hearts From Type 2 Diabetic Mice. Diabetes, 2012, 61, 3094-3105.	0.6	77
150	Detection, monitoring, and management of trastuzumabâ€induced left ventricular dysfunction: an actual challenge. European Journal of Heart Failure, 2012, 14, 130-137.	7.1	77
151	Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. Breast Cancer Research and Treatment, 2012, 133, 511-521.	2.5	43
152	Le alterazioni elettrocardiografiche espressione di cardiotossicitÃ. Journal of Cardiovascular Echography, 2011, 21, 55-59.	0.4	0
153	Early Identification of Left Ventricular Dysfunction Induced by Trastuzumab. Journal of the American College of Cardiology, 2011, 58, 2698-2699.	2.8	3
154	1114 POSTER The Anticancer MTOR-inhibitor Temsirolimus Induces Cardiotoxicity in a Mouse Model. European Journal of Cancer, 2011, 47, S128.	2.8	0
155	P114 The anti-neoplastic ErbB2-antibody 2C4 produces left ventricular dysfunction in murine hearts. Breast, 2011, 20, S20.	2.2	0
156	Complete atrioventricular block in a patient with intracardiac metastases from malignant melanoma. European Heart Journal Cardiovascular Imaging, 2011, 12, 636-636.	1.2	2
157	Playing with Cardiac â€œRedox Switchesâ€: The â€œHNO Wayâ€•to Modulate Cardiac Function. Antioxidants and Redox Signaling, 2011, 14, 1687-1698.	5.4	101
158	Early detection of cardiac dysfunction induced by the mTOR inhibitor temsirolimus.. Journal of Clinical Oncology, 2011, 29, e13612-e13612.	1.6	0
159	The ErbB2-antibody 2C4 and cardiac dysfunction in mice.. Journal of Clinical Oncology, 2011, 29, e11040-e11040.	1.6	0
160	PDE5A suppression of acute Î²-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation. Basic Research in Cardiology, 2010, 105, 337-347.	5.9	92
161	Nitroxyl enhances myocyte Ca2 transients by exclusively targeting SR Ca2 -cycling. Frontiers in Bioscience - Elite, 2010, E2, 614-626.	1.8	36
162	Prognostic Significance of Left Atrial Volume Dilatation in Patients with Hypertrophic Cardiomyopathy. Journal of the American Society of Echocardiography, 2009, 22, 76-81.	2.8	75

#	Article	IF	Citations
163	Phospholamban Thiols Play a Central Role in Activation of the Cardiac Muscle Sarcoplasmic Reticulum Calcium Pump by Nitroxyl. Biochemistry, 2008, 47, 13150-13152.	2.5	91
164	Reversal of Cardiac Hypertrophy and Fibrosis From Pressure Overload by Tetrahydrobiopterin. Circulation, 2008, 117, 2626-2636.	1.6	223
165	Compartmentalization of Cardiac Î²-Adrenergic Inotropy Modulation by Phosphodiesterase Type 5. Circulation, 2007, 115, 2159-2167.	1.6	151
166	Nitroxyl Improves Cellular Heart Function by Directly Enhancing Cardiac Sarcoplasmic Reticulum Ca 2+ Cycling. Circulation Research, 2007, 100, 96-104.	4.5	209
167	Nitroxyl increases force development in rat cardiac muscle. Journal of Physiology, 2007, 580, 951-960.	2.9	89
168	The pharmacology of nitroxyl (HNO) and its therapeutic potential: Not just the janus face of NO11This review is dedicated to the career of Prof. Herbert T. Nagasawa, a pioneer in the field of HNO chemistry, biochemistry and pharmacology.. , 2007, 113, 442-458.		222
169	The Activation of Metabolites of Nitric Oxide Synthase by Metals Is Both Redox and Oxygen Dependent: A New Feature of Nitrogen Oxide Signaling. Antioxidants and Redox Signaling, 2006, 8, 1363-1371.	5.4	27
170	Discriminating formation of HNO from other reactive nitrogen oxide species. Free Radical Biology and Medicine, 2006, 40, 1056-1066.	2.9	99
171	Peroxynitrite and myocardial contractility: In vivo versus in vitro effects. Free Radical Biology and Medicine, 2006, 41, 1606-1618.	2.9	53
172	Compartmentalized Phosphodiesterase-2 Activity Blunts Î²-Adrenergic Cardiac Inotropy via an NO/cGMP-Dependent Pathway. Circulation Research, 2006, 98, 226-234.	4.5	252
173	Metalloproteinase Inhibitor Counters High-Energy Phosphate Depletion and AMP Deaminase Activity Enhancing Ventricular Diastolic Compliance in Subacute Heart Failure. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 506-513.	2.5	30
174	Comparison of the Chemical Biology of NO and HNO: An Inorganic Perspective. Progress in Inorganic Chemistry, 2005, , 349-384.	3.0	11
175	Comparison of the NO and HNO Donating Properties of Diazeniumdiolates:â€‰ Primary Amine Adducts Release HNO in Vivo. Journal of Medicinal Chemistry, 2005, 48, 8220-8228.	6.4	118
176	Calcitonin Gene-Related Peptide In Vivo Positive Inotropy Is Attributable to Regional Sympatho-Stimulation and Is Blunted in Congestive Heart Failure. Circulation Research, 2005, 96, 234-243.	4.5	58
177	Mechanism of Aerobic Decomposition of Angeli's Salt (Sodium Trioxodinitrate) at Physiological pH. Journal of the American Chemical Society, 2005, 127, 722-731.	13.7	105
178	The Chemical Dynamics of NO and Reactive Nitrogen Oxides: A Practical Guide. Current Molecular Medicine, 2004, 4, 723-740.	1.3	41
179	Determinants of atrial fibrillation development in patients with hypertrophic cardiomyopathy. American Journal of Cardiology, 2004, 94, 895-900.	1.6	114
180	Hemodynamic effects of isometric exercise in hypertrophic cardiomyopathy: Comparison with normal subjects. Journal of Nuclear Cardiology, 2003, 10, 154-160.	2.1	9

#	Article	IF	Citations
181	Myocardial Collagen Turnover in Hypertrophic Cardiomyopathy. Circulation, 2003, 108, 1455-1460.	1.6	185
182	Dobutamine Stress Echocardiography in Hypertrophic Cardiomyopathy. Cardiology, 2003, 100, 93-100.	1.4	11
183	Comparison of hemodynamic adaptation to orthostatic stress in patients with hypertrophic cardiomyopathy with or without syncope and in vasovagal syncope. American Journal of Cardiology, 2002, 89, 1405-1410.	1.6	17
184	Determinants and clinical significance of natriuretic peptides and hypertrophic cardiomyopathy. European Heart Journal, 2001, 22, 1328-1336.	2.2	58
185	PED/PEA-15 gene controls glucose transport and is overexpressed in type 2 diabetes mellitus. EMBO Journal, 1998, 17, 3858-3866.	7.8	157
186	Abnormal glucose transport and GLUT1 cell-surface content in fibroblasts and skeletal muscle from NIDDM and obese subjects. Diabetologia, 1997, 40, 421-429.	6.3	36
187	O-51: Overexpression of the MAT-1 oncogene in non-insulin-dependent diabetes. Experimental and Clinical Endocrinology and Diabetes, 1996, 104, 63-63.	1.2	0